Engineered immune cells take on deadly brain tumors
NCT ID NCT07180927
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This study tests a new treatment called 4sCAR-DLL3 CAR-T cells for people with DLL3-positive brain tumors, including glioblastoma. The therapy uses a patient's own immune cells that are modified in a lab to target and attack tumor cells. The trial will enroll 30 participants aged 2 to 70 whose tumors have come back or not responded to standard treatments. The main goal is to check safety and see if the cells can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA OF CEREBELLUM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immuno Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
4sCAR-DLL3 CAR-T cells (a type of immune cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for aggressive brain tumors like glioblastoma that have not responded to standard therapy.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to all patients. CAR-T therapy can cause serious side effects like cytokine release syndrome or neurotoxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.